Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Abili-T Trial in Secondary Progressive MS On-Schedule With Top-Line Results Expected in Early Q4 Conference Call Scheduled Today at 4:30 PM ET THE WOODLANDS, TX -- (Marketwired) -- 08/11/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical …